Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20482729 | 0.91 | PRCP (0.44) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP | |
| SCHEMBL4181457 | 0.91 | PRCP (0.44) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP | |
| SCHEMBL4170855 | 0.91 | PRCP (0.44) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP | |
| SCHEMBL4173733 | 0.91 | PRCP (0.44) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP | |
| SCHEMBL13875186 | 0.91 | PRCP (0.44) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP | |
| SCHEMBL4170860 | 0.91 | PRCP (0.44) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP | |
| SCHEMBL4173032 | 0.84 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL4188457 | 0.84 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL5547748 | 0.75 | CXCR4 (0.42) | CYP2D6CXCR4 | |
| SCHEMBL3869434 | 0.74 | PRCP (0.43) | CHRNB2CHRNA4CHRNB4CHRNA2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SLC10A1, CYP11B2, CYP4F3 | CHRNB2 4068/4885CHRNA4 4207/4885CHRNB4 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.